AbbVie (United Kingdom)

Recent papers from AbbVie (United Kingdom)

1. Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in KoreaOcular Immunology and Inflammation · 2026
2. The Role of Continuous Glucose Monitoring in Managing Hyperglycaemia First Detected in Pregnancy: A Narrative ReviewDiabetes Obesity and Metabolism · 2026
3. The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi ArabiaClinicoEconomics and Outcomes Research · 2026
4. P182 Real-world comparative effectiveness of upadacitinib in psoriatic arthritis: evaluation of switching to upadacitinib versus tumor necrosis factor inhibitors or interleukin-17 inhibitors after first-line tumor necrosis factor inhibitorsLara D. Veeken · 2026
5. P185 Real-world effectiveness of upadacitinib on early pain control in patients with axial spondyloarthritis: interim results from the UPSTAND observational studyLara D. Veeken · 2026
6. P178 Long-term safety of upadacitinib across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis encompassing ∼17,000 patient-years of clinical trial dataLara D. Veeken · 2026
7. P105 Correlation between patient-reported and clinical outcomes in patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib: real-world data from ENDEAVOURLara D. Veeken · 2026
8. Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World StudyRheumatology and Therapy · 2026
9. Assessment of Methods and Attributes Used to Characterize Skin Quality: A Systematic Literature ReviewDermatologic Surgery · 2026
10. Global Recommendations for Facial Rejuvenation Using a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid InjectableJournal of Cosmetic Dermatology · 2026
11. P0577real world durability of response and remission with upadacitinib in Ulcerative Colitis: a multi-centre studyJournal of Crohn s and Colitis · 2026
12. Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the conditionBMC Medicine · 2025
13. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyJournal of Clinical Oncology · 2025
14. Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): demonstration of savings from a societal perspective in the UKJournal of Medical Economics · 2025
15. A Prospective, Open‐Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid InjectableJournal of Cosmetic Dermatology · 2025
16. European Health Technology Assessment Considerations Related to Gene Therapies in Eyecare: The Neovascular Age-Related Macular Degeneration ExampleJournal of Market Access & Health Policy · 2025
17. Assessment of Brain Volume and Cortical Thickness in People with HIV and Major Depressive DisorderCurrent HIV Research · 2025
18. Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)Current Medical Research and Opinion · 2025
19. Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS)Current Medical Research and Opinion · 2025
20. Anatomic biomarkers as potential endpoints in diabetic macular edema: A systematic literature review with identification of macular volume as a key surrogate for visual acuitySurvey of Ophthalmology · 2025